{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:03Z","timestamp":1790610783485,"version":"4.1.0"},"reference-count":27,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVICTOR BABE\u0218\u201d UNIVERSITY OF MEDICINE AND PHARMACY TIMISOARA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: X-linked hypophosphatemia (XLH) is the most common form of inherited rickets, caused by pathogenic mutations in the PHEX gene (phosphate-regulating endopeptidase homolog, X-linked). These mutations increase fibroblast growth factor 23 (FGF23) activity, resulting in renal phosphate wasting and defective bone mineralization. The disorder manifests with variable skeletal, dental, and extraskeletal involvement. Conventional therapy with oral phosphate and active vitamin D offers limited benefit, whereas burosumab, an anti-FGF23 monoclonal antibody, has transformed disease management. Methods: The index case, a 43-year-old woman, remained undiagnosed until adulthood, leading to severe deformities, osteoarthritis, chronic pain, and complete edentulism. Her 55-year-old sister presented with a milder phenotype. The 20-year-old nephew, diagnosed in childhood and intermittently treated with phosphate and alfacalcidol, developed short stature, genu varum, and early degenerative joint disease. Following genetic confirmation, he began burosumab therapy, which normalized phosphate metabolism, reduced pain, and improved mobility. Results: XLH demonstrates marked intrafamilial phenotypic variability despite identical PHEX mutations. In this series, delayed recognition in adults led to irreversible skeletal deformities, osteoarthritis, and dental loss, whereas earlier diagnosis in the younger patient allowed timely intervention. Conventional therapy only partially mitigated complications, while burosumab achieved rapid biochemical correction and symptomatic improvement. This contrast highlights the importance of early genetic testing, family screening, and prompt initiation of targeted treatment. Conclusions: This family cluster underscores the critical need for early diagnosis, genetic confirmation, cascade screening, and lifelong multidisciplinary care. Burosumab represents a therapeutic paradigm shift in XLH, capable of altering disease trajectory when initiated early.<\/jats:p>","DOI":"10.3390\/jcm14217496","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:14:04Z","timestamp":1761207244000},"page":"7496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["X-Linked Hypophosphatemia in a Family Cohort: Clinical Variability, Genetic Confirmation and Modern Therapeutic Perspectives"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3883-2438","authenticated-orcid":false,"given":"Oana","family":"Popa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University Clinic of Endocrinology, Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Department of Endocrinology, \u201cPius Br\u00e2nzeu\u201d County Emergency Clinic Hospital Timi\u0219oara, 300723 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7135-1380","authenticated-orcid":false,"given":"Melania","family":"Bala\u0219","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Clinic of Endocrinology, Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Department of Endocrinology, \u201cPius Br\u00e2nzeu\u201d County Emergency Clinic Hospital Timi\u0219oara, 300723 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6032-6246","authenticated-orcid":false,"given":"Ioana","family":"Golu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Clinic of Endocrinology, Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Department of Endocrinology, \u201cPius Br\u00e2nzeu\u201d County Emergency Clinic Hospital Timi\u0219oara, 300723 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9547-2061","authenticated-orcid":false,"given":"Daniela","family":"Amz\u0103r","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Clinic of Endocrinology, Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Department of Endocrinology, \u201cPius Br\u00e2nzeu\u201d County Emergency Clinic Hospital Timi\u0219oara, 300723 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Dorogi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Clinic of Endocrinology, Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Department of Endocrinology, \u201cPius Br\u00e2nzeu\u201d County Emergency Clinic Hospital Timi\u0219oara, 300723 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-1650","authenticated-orcid":false,"given":"Mihaela","family":"Vlad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Clinic of Endocrinology, Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Department of Endocrinology, \u201cPius Br\u00e2nzeu\u201d County Emergency Clinic Hospital Timi\u0219oara, 300723 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/adc.83.3.192","article-title":"The molecular background to hypophosphataemic rickets","volume":"83","author":"Rowe","year":"2000","journal-title":"Arch. Dis. Child."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1073\/pnas.95.9.5372","article-title":"Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities","volume":"95","author":"Beck","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1055\/a-2159-8429","article-title":"X-linked familial hypophosphatemia: A case report of a 27-year-old male and review of literature","volume":"55","author":"Abdullah","year":"2023","journal-title":"Horm. Metab. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","article-title":"The International X-Linked Hypophosphataemia (XLH) Registry (NCT03193476): Rationale for and Description of an International Observational Study","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Baroncelli, G.I., and Mora, S. (2021). X-linked hypophosphatemic rickets: Multisystemic disorder in children requiring multidisciplinary management. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.688309"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","article-title":"The International X-linked hypophosphatemia (XLH) registry: First interim analysis of baseline demographic, genetic and clinical data","volume":"18","author":"Ariceta","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1941","DOI":"10.1002\/mgg3.1941","article-title":"X-linked hypophosphatemic rickets: Description of seven new variants in patients followed up in reference hospitals in Rio de Janeiro","volume":"10","author":"Torrini","year":"2022","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"107556","DOI":"10.1016\/j.jsb.2020.107556","article-title":"Alterations of bone material properties in adult patients with X-linked hypophosphatemia (XLH)","volume":"211","author":"Gamsjaeger","year":"2020","journal-title":"J. Struct. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Park, P.G., Lim, S.H., Lee, H., Ahn, Y.H., Cheong, H.I., and Kang, H.G. (2021). Genotype and phenotype analysis in X-linked hypophosphatemia. Front. Pediatr., 9.","DOI":"10.3389\/fped.2021.699767"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Brener, R., Zeitlin, L., Lebenthal, Y., and Brener, A. (2022). Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.947814"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e10672","DOI":"10.1002\/jbm4.10672","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","volume":"6","author":"Gadion","year":"2022","journal-title":"JBMR Plus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41439-020-0095-1","article-title":"Phenotypes of a Family with XLH with a Novel PHEX Mutation","volume":"7","author":"Yamamoto","year":"2020","journal-title":"Hum. Genome Var."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"116763","DOI":"10.1016\/j.bone.2023.116763","article-title":"X-Linked Hypophosphatemia in Four Generations Due to an Exon 13\u201315 Duplication in PHEX, in the Absence of the c.*231A>G Variant","volume":"172","author":"Sanchez","year":"2023","journal-title":"Bone"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of Adult Patients with X-Linked Hypophosphatemia Caused by PHEX Gene Mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of Therapy in X-Linked Hypophosphatemic Rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab Therapy in Children with X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/clinem\/dgac518","article-title":"Long-Term Burosumab Administration Is Safe and Effective in Adults with X-Linked Hypophosphatemia","volume":"108","author":"Weber","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00223-025-01433-2","article-title":"Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK","volume":"116","author":"Bubbear","year":"2025","journal-title":"Calcif. Tissue Int."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Abdullah, A., Wuersching, S.N., Kollmuss, M., Poxleitner, P., Dewenter, I., Brandenburg, L.S., Steybe, D., Fegg, F.N., Smolka, W., and Otto, S. (2023). X-Linked Hypophosphatemia: Does Targeted Therapy Modify Dental Impairment?. J. Clin. Med., 12.","DOI":"10.3390\/jcm12247546"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41405-024-00223-6","article-title":"Characteristics of Oral Health of Patients with X-Linked Hypophosphatemia: Case Reports and Literature Review","volume":"10","author":"Arhar","year":"2024","journal-title":"BDJ Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","article-title":"X-Linked Hypophosphatemia: Management and Treatment Prospects","volume":"86","author":"Lambert","year":"2019","journal-title":"Jt. Bone Spine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: A systematic literature review","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Alsagheir, A.I., Bin-Abbas, B., Alghamdi, N.M., Alhuthil, R.T., Murad, S.A., Husein, T.H., Mughal, M.Z., Alsabban, Z.E., Almarzoug, L.M., and Ramzan, K. (2025). Quality of life of 26 family members from four generations with X-linked hypophosphatemia: A cross-sectional study. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1544016"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Akta, C., Wenzel-Schwarz, F., Stauffer, A., Kranzl, A., Raimann, A., Kocijan, R., Ganger, R., and Mindler, G.T. (2023). The ankle in XLH: Reduced motion, power and quality of life. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1111104"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:26:20Z","timestamp":1761207980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":27,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14217496"],"URL":"https:\/\/doi.org\/10.3390\/jcm14217496","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}